国际眼科纵览

• 综述 • 上一篇    下一篇

糖尿病视网膜病变药物治疗的研究进展

刘朝辉 高晓虹 栗改云 马涛 李康   

  1. 030001太原,山西医科大学(刘朝辉);030002太原,山西省眼科医院(高晓虹、栗改云、马涛、李康)
  • 收稿日期:2016-01-18 出版日期:2016-08-22 发布日期:2016-09-08
  • 通讯作者: 高晓虹,Email:violetdaisynn@126.com E-mail:violetdaisynn@126.com

Progress in medication for diabetic retinopathy

LIU Zhao-hui1, GAO Xiao-hong2, LI Gai-yun2, MA Tao2, LI Kang2   

  1. 1. Shanxi Medical University, Taiyuan 030001, China; 2. Shanxi Eye Hospital, Taiyuan 030002, China
  • Received:2016-01-18 Online:2016-08-22 Published:2016-09-08
  • Contact: GAO Xiao-hong, Email: violetdaisynn@126.com E-mail:violetdaisynn@126.com

摘要:

随着糖尿病视网膜病变(diabetic retinopathy, DR)发病机制的深入研究,目前对DR的药物治疗取得了一定的成果,包括糖皮质激素、抗血管内皮细胞生长因子、抗血小板源性生长因子、非甾体类消炎药以及改善视神经功能的药物。目前治疗糖尿病黄斑水肿,玻璃体注药治疗特别是抗血管内皮细胞生长因子药物已逐渐推广。

Abstract:

With the update of the pathologic mechanisms of diabetic retinopathy (DR), currently medication therapy has also made some progress, including corticosteroids, anti-vascular endothelial growth factor, anti-platelet derived growth factor, non-steroidal anti-inflammatory drugs, as well as drugs to improve the function of the optic nerve. Currently, in the treatment of diabetic macular edema, intravitreal pharmacotherapies, especially anti-vascular endothelial growth factor (anti-VEGF) agents, have gained popularity.